Central Nervous System Stimulants and Drugs that Suppress Appetite

Aagaard, Lise

doi:10.1016/b978-0-444-63407-8.00001-0

Cited by 4 publications

(4 citation statements)

References 184 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A common side effect of AChE inhibition treatments is anorexia [ 34 , 35 ], which strengthens the importance of natural AChE inhibitors as potential deterrents of predators such as fishes. Furthermore, the olfactory dysfunction in Alzheimer’s disease has also been demonstrated [ 36 ].…”

Section: Resultsmentioning

confidence: 99%

Bioactive Bromotyrosine-Derived Alkaloids from the Polynesian Sponge Suberea ianthelliformis

et al. 2018

View full text Add to dashboard Cite

Herein, we describe the isolation and spectroscopic identification of eight new tetrabrominated tyrosine alkaloids 2–9 from the Polynesian sponge Suberea ianthelliformis, along with known major compound psammaplysene D (1), N,N-dimethyldibromotyramine, 5-hydroxy xanthenuric acid, and xanthenuric acid. Cytotoxicity and acetylcholinesterase inhibition activities were evaluated for some of the isolated metabolites. They exhibited moderate antiproliferative activity against KB cancer cell lines, but psammaplysene D (1) displayed substantial cytotoxicity as well as acetylcholinesterase inhibition with IC50 values of 0.7 μM and 1.3 μM, respectively.

show abstract

Section: Resultsmentioning

confidence: 99%

Bioactive Bromotyrosine-Derived Alkaloids from the Polynesian Sponge Suberea ianthelliformis

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Moreover, almost all these drugs have some side effects like nausea, vomiting, and diarrhea. During their injection, they cross the intestines and spread throughout the body with blood, and finally cross the blood-brain barrier to produce a curing effect (86). Creating nanoparticle drugs can help us to minimize these side effects in various ways.…”

Section: Application Of Nanotechnology In Ad Treatmentmentioning

confidence: 99%

Multiple Approaches for the Management of Alzheimer's Disease: Natural Compounds, FDA Approved Drugs, and Nanotechnology Interventions

Azhar¹,

Azhar²,

Azhar³

2022

Cell Mol Biol (Noisy-le-grand)

View full text Add to dashboard Cite

Alzheimer's disease is the most common in the elderly population. Due to its irreversible and progressive nature, it gained more attention for early management. In this regard, several new therapeutic targets, such as degrading neurotransmitter enzymes, amyloid cascade enzymes, and monoamine oxidases, have been explored. Inhibition of these targets with natural and synthetic compounds and dietary supplements has been traditionally exercised for decades in the etiology of AD. Secondary metabolites obtained from natural resources are in the trend to use against these targets. The purpose of this review is to provide a brief introduction to AD along with the related concept of several therapeutic compounds involved in the progression of the disease and its management using different natural compounds against selected targets.

show abstract

“…Oral formulations for centrally acting drugs necessitate using comparatively high doses so that the fraction reaching the brain, after overcoming oral barriers of absorption, hepatic metabolism, distribution and finally traversing the blood-brain barrier (BBB), has therapeutic significance. Additionally, most of these dosage forms show high incidence of side effects due to their action in the peripheral tissues such as nausea, vomiting, and diarrhea (19) . Minimizing these side effects improves the patient's quality of life.…”

Section: Drug Delivery Strategies For Admentioning

confidence: 99%

Nanotechnology-based drug delivery systems for Alzheimer's disease management: Technical, industrial, and clinical challenges

Wen

El-Salamouni

El-Refaie

et al. 2017

Journal of Controlled Release

184

View full text Add to dashboard Cite

Central Nervous System Stimulants and Drugs that Suppress Appetite

Cited by 4 publications

References 184 publications

Bioactive Bromotyrosine-Derived Alkaloids from the Polynesian Sponge Suberea ianthelliformis

Bioactive Bromotyrosine-Derived Alkaloids from the Polynesian Sponge Suberea ianthelliformis

Multiple Approaches for the Management of Alzheimer's Disease: Natural Compounds, FDA Approved Drugs, and Nanotechnology Interventions

Nanotechnology-based drug delivery systems for Alzheimer's disease management: Technical, industrial, and clinical challenges

Contact Info

Product

Resources

About